Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest announcement is out from NKGen Biotech ( (NKGN) ).
NKGen Biotech, Inc. has granted special one-time stock options to its CEO, Paul Song, and interim CFO, James Graf, as recognition for their contributions post the company’s public transaction and their deferred 2024 compensation. These stock options are part of the company’s strategy to address financial challenges and incentivize its leadership, with Song’s options vesting over four years and Graf’s over three years.
More about NKGen Biotech
NKGen Biotech, Inc. operates in the biotechnology industry, focusing on developing innovative biomedical solutions. The company is involved in public transactions and aims to navigate financial challenges while rewarding key executives for their contributions.
YTD Price Performance: -81.05%
Average Trading Volume: 1,376,189
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $18.51M
See more data about NKGN stock on TipRanks’ Stock Analysis page.
